12:00 AM
May 21, 2007
 |  BioCentury  |  Emerging Company Profile

Emiliem: Not just any kinase

Emiliem Inc. is using its K-STAR platform to design compounds that specifically target multiple kinases known to have roles in cancer while simultaneously avoiding kinases that are important to healthy tissues. By applying its algorithm to publicly available information about kinase structure, biology and related ligands, the company believes it can shave two years off development time, cut costs by an order of magnitude and deliver more predictable safety and efficacy.

Dale Johnson, president and CEO of Emiliem (Emeryville, Calif.), told BioCentury that the starting point for K-STAR (kinase structure target activity relationship) is an extensive body of existing knowledge on kinases and their associations with cancer and toxicities.


Read the full 541 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >